Lv2
147 积分 2023-10-09 加入
SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions
1天前
已完结
Mechanisms Underlying Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer
16天前
已完结
Turning cold into hot: emerging strategies to fire up the tumor microenvironment
16天前
已完结
Up‐front autologous stem cell transplant in peripheral T‐cell lymphoma patients achieving complete response after first‐line treatment: A multicentre real‐world analysis
29天前
已完结
Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience
30天前
已完结
Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trial
1个月前
已完结
Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma
1个月前
已完结
Selinexor plus tislelizumab in patients with relapsed/refractory NK/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial
1个月前
已完结
Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial
1个月前
已完结
Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma
1个月前
已完结
皖公网安备34019202002308
